{"contentid": 488395, "importid": NaN, "name": "More manufacturing woes add to J&J's vaccine worries", "introduction": "It has been a difficult period for Johnson & Johnson\u00e2\u0080\u0099s coronavirus vaccine, with the US regulator ordering shutting a manufacturing facility owned by Emergent BioSolutions.", "content": "<p><span style=\"font-weight: 400;\">It has been a difficult period for Johnson &amp; Johnson&rsquo;s (NYSE: JNJ) coronavirus vaccine, with the US regulator ordering shutting a manufacturing facility owned by Emergent BioSolutions (NYSE: EBS).</span></p>\n<p><span style=\"font-weight: 400;\">Operations at the site have been shut down pending completion of an inspection, &ldquo;and remediation of any resulting findings,&rdquo; </span><a href=\"https://www.sec.gov/ix?doc=/Archives/edgar/data/1367644/000136764421000066/ebs-20210419.htm\"><span style=\"font-weight: 400;\">a filing</span></a><span style=\"font-weight: 400;\"> with the US Securities and Exchange Commission (SEC) sets out.</span></p>\n<p><span style=\"font-weight: 400;\">The setback comes just days after use of J&amp;J&rsquo;s vaccine was </span><a href=\"https://www.thepharmaletter.com/article/cdc-and-fda-recommend-pausing-j-j-covid-19-vaccine-use\"><span style=\"font-weight: 400;\">paused in the USA</span></a><span style=\"font-weight: 400;\">, while regulators investigate a possible link with a rare kind of blood clot.</span></p>\n<h2><strong>Working with Emergent</strong></h2>\n<p><span style=\"font-weight: 400;\">Emergent has had a chequered history when it comes to manufacturing at the site, which is also used to produce AstraZeneca&rsquo;s (LSE: AZN) coronavirus vaccine.&nbsp;</span></p>\n<p><span style=\"font-weight: 400;\">A materials mix up in March led to around 15 million doses being wasted, while an additional batch of up to 15 million doses of the AstraZeneca jab was junked over fears of a possible contamination.</span></p>\n<p><span style=\"font-weight: 400;\">In April, the US regulator stepped in to hand over responsibility for manufacturing the vaccine at the facility to J&amp;J.</span></p>\n<p><span style=\"font-weight: 400;\">The affected site in Maryland, USA, is not yet authorized by the US regulator to deliver the J&amp;J vaccine. The company is approved to produce doses at a base in Europe, with fill and finish services being provided by Catalent (NYSE: CTLT) in the USA.</span></p>\n<p><span style=\"font-weight: 400;\">J&amp;J chose Emergent to help produce its viral-vector based coronavirus vaccine, dubbed Ad26.COV2-S, in July 2020, with a deal valued at approximately $480 million for the first two years.</span></p>\n<p><span style=\"font-weight: 400;\">That agreement came shortly after the US Department of Health and Human Services (HHS) agreed to pay Emergent hundreds of millions to develop capacity for COVID-19 vaccine and therapeutic manufacturing.</span></p>", "date": "2021-04-20 10:13:00", "meta_title": NaN, "meta_keywords": "vaccine, manufacturing, Emergent, coronavirus, regulator, shut, facility, NYSE, site, doses, million, produce, ordering, difficult, Johnson, period, owned", "meta_description": NaN, "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-20 10:09:03", "updated": "2021-04-21 10:13:19", "access": NaN, "url": "https://www.thepharmaletter.com/article/more-manufacturing-woes-add-to-j-j-s-vaccine-worries", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "biotech_manufacturing_big-2.jpg", "image2id": "biotech_manufacturing_small-3.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Infectious diseases, Vaccines", "topic_tag": "Coronavirus, Focus On, Production, Public health, US FDA", "geography_tag": "UK, USA", "company_tag": "AstraZeneca, Emergent BioSolutions, Johnson & Johnson", "drug_tag": "Ad26.COV2-S, recombinant, COVID-19 Vaccine Janssen, Vaxzevria", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-20 10:13:00"}